Communication to Shareholders, page-47

Whilst it's one thing to complain about communication from ADO or any other listed company it's interesting if people actually read what is communicated and note it or if they need re-announcements which then brinngs its own complaints.

The last quarterly update was crystal clear that the next update in regards to the clinical trials would be when the trials have been completed and not during the trials. Below is the text.

Clinical Trials
European Clinical Trial
A Spanish CRO has been contracted to conduct the Prospective Clinical Trial for the EuGeni Covid19 RAT. During the quarter, a significant amount of work was undertaken to prepare the clinical protocols and screen trial sites across Europe. The final site selection and site visits, a key step in the
clinical trial process, have now been completed. At the time of writing, ethics protocols for each site were under review by the individual study sites and the CRO. It is anticipated that patient recruitment will have commenced at the first trial site by end April.
Once the trial has commenced, to ensure the integrity of the clinical trial and adhere to the ethics protocol of the trial, AnteoTech will refrain from reporting or commenting on the trial or its progress until it is complete and all reports are finalised.

Australian Clinical Trial
The clinical trial underway in Victoria is ongoing and continues to progress as planned.AnteoTech will provide information on the outcome at the conclusion of the trial and on receipt of a final report.